Information Provided By:
Fly News Breaks for April 11, 2019
NBIX
Apr 11, 2019 | 17:01 EDT
Evercore ISI analyst Ravi Mehrotra initiated Neurocrine with an Outperform rating and a price targets of $113. The analyst cites his above-consensus estimates for Ingrezza at $1.76B, the multiple opportunities for long term upside to penetration rates, and its pipeline that is not being fully appreciated.